STUDY DESIGN AND METHODS:
Fourteen healthy male subjects underwent one simulated ECP procedure without reinfusion of buffy coats (BCs) in a two-center, open-label, prospective trial. Baseline peripheral blood BC, apheresis-separated untreated BC (BC1), and photoactivated BC (BC2) were evaluated in culture for viability by dye exclusion, apoptosis by annexin V binding, and cell proliferation response to phytohemagglutinin (PHA) stimulation by bromodeoxyuridine (BrdU) incorporation.
RESULTS: Photoactivation (BC2) resulted in 88%
expression of annexin V by Day 1 of culture compared with 37 and 39% for baseline and untreated BC1. Cell viability by propidium iodide exclusion was reduced to 10% in BC2 on Day 1 versus 65 and 60% for baseline and BC1. The proliferative response to PHA stimulation was 97% inhibited in the photoactivated BC2.
CONCLUSIONS: These results demonstrate that the mechanical processes used for cell separation and processing of the BC in the absence of photoactivation do not induce a significant amount of apoptosis compared to the standard ECP with methoxsalen and UVA photoactivation. E xtracorporeal photopheresis (ECP) has been used to treat a number of immunologic diseases, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] although cutaneous T-cell lymphoma is currently the only Food and Drug Administrationapproved indication. 17, 18 An ECP treatment is composed of the ex vivo exposure of autologous white blood cells (WBCs) to a liquid formulation of 8-methoxypsoralen (THERAKOS UVADEX, Therakos, Inc.) and ultraviolet A (UVA) light, followed by the subsequent reinfusion of the cells to the subject. 19, 20 ABBREVIATIONS: BC(s) 5 buffy coat(s); BrdU 5 bromodeoxyuridine; ECP 5 extracorporeal photopheresis; PHA 5 phytohemagglutinin.
Therakos photopheresis systems are the only worldwide approved devices where illumination chamber is integrated with the cell separation component. The market approval in the United States was obtained for ECP in 1988 for skin manifestation of cutaneous T-cell lymphoma, and the second-generation device, the UVAR XTS system, was approved in the United States in 1999. The CELLEX system, the third-generation system, was approved in the United States in 2009. 19 The biologic mechanism explaining the effectiveness of ECP has not been fully elucidated, and it may differ between disease states. It is well established that a primary event leading to the clinical effect is exposure of a patient's WBCs to methoxsalen and UVA light. This treatment leads to induction of normal programmed cell death (i.e., apoptosis) in the treated buffy coat (BC) cells, which in turn initiates a number of secondary, diseasedependent, responses when reinfused into the patient. 1, 20, 21 A recent in vitro study has indicated that it might be possible to modulate the kinetics of apoptosis in WBC subpopulations by adjusting the duration of incubation with methoxsalen. 22 The therapeutic implications of this finding are yet to be determined. Some investigators have posited that the apoptosis observed after ECP treatment might be primarily caused by the mechanical stresses, such as shear, turbulence, and centrifugal forces and pressures, rather than the treatment with methoxsalen. 1, 21, 23, 24 It is important to determine if these effects may have a significant contribution before launching clinical trials that include a sham control to address the biologic mechanisms of ECP. The objective of this study was to evaluate the effect of mechanical cell processing through the photopheresis instrument on induction of apoptosis, proliferation, and viability of mononuclear cells (MNCs).
MATERIALS AND METHODS

Subjects
This study was conducted under an investigation device exception reviewed by the US Food and Drug Administration and approved by the local institutional review boards of each participating site. Subjects were fully informed of the study and consented to participation. Studied subjects were healthy male volunteers 21 to 54 years of age more than 40 kg in good physical health and no clinically significant abnormal laboratory results for chemistry and partial thromboplastin time tests at screening and no clinically significant abnormal WBC, red blood cell (RBCs), or platelet (PLT) cell counts. The selection of male only subjects was primarily driven for a potential safety concern for inadvertent infusion of 8-methoxypsoralen, should there will be an error, to females of childbearing age. Additionally, the subjects tested negative for drugs of abuse, as confirmed by laboratory drug screen, and were negative for human immunodeficiency virus, hepatitis B, and hepatitis C, per laboratory analysis. The subjects were not taking any concomitant medications; however multivitamins were considered acceptable. 
BC collection
Using both the XTS and CELLEX systems, WBC BCs were collected following the manufacturer's instructions for use. Before addition of UVADEX, RBCs and plasma in the extracorporeal circuit were returned to the subject, and they were disconnected from the circuit. UVADEX was added to the collected BC that was exposed to UVA (1.5 J/ cm 2 and wavelength of 320-400 nm) and then removed from the device. The BC portion of the processed blood removed during the procedure was not returned back to the subject. Samples were collected from the subject and the BC as described below.
Sample treatment and collection
A 20-mL baseline peripheral whole blood sample from the subject immediately before the procedure was collected into an ACD tube (Cat # 364606, Becton Dickinson; Fig. 1B ). The BC1 sample was aseptically obtained from the BC recirculation bag at the completion of the cell collection phase of the treatment but before ex vivo photoactivation by first gently mixing the contents of the recirculation bag and then attaching a 20-to 30-mL sterile syringe to the port. After flushing the port two to three times, 20 mL of the cell suspension was removed from the bag and transferred to two ACD tubes. UVADEX was then added (at 0.017 mL UVADEX per mL of BC/treatment volume) to the collected BC and photoactivation was initiated to deliver approximately 1.5 J/ cm 2 . Upon completion of the ex vivo photoactivation procedure, the BC2 sample was aseptically obtained from the BC recirculation bag and transferred to ACD tubes as described above. The remainder of the BC was discarded. The samples were packed and shipped to a central laboratory (Wuxi Apptec, Inc.) for further processing, culture, and assays. evaluable subjects completing the study. (B) Collection and sampling sequence. Subjects were disconnected from the collection device before UVADEX addition, and BCs were not returned to the subjects.
Cell preparation and viability
Anticoagulated whole blood baseline samples were diluted 1:1 in 13 phosphate-buffered saline (PBS), layered over Ficoll-Paque PLUS (Cat # 17-1440-02, GE Healthcare), and centrifuged for 30 minutes at 400 3 g. The lymphocyte layer was then removed, rinsed with 13 PBS, and treated with ammonium chloride potassium lysis buffer (Cat # A10492, Life Technologies) to lyse any remaining RBCs. The cell suspension was then resuspended in RPMI 1640 (Cat # 11875085, Life Technologies). BC1 and BC2 samples required no additional processing. The cell suspensions were then counted using a hemocytometer; viabilities were determined by trypan blue exclusion assay (Day 0) then placed into culture at 0.5 3 10 6 to 1.5 3 10 6 cells/mL in multiwell plates for up to 7 days at 98% humidity 37 6 28C/5 6 2% CO 2 . Viability of the cells was determined by trypan blue exclusion assay after 1, 3, and 7 days in culture to assess cell death over the 7-day period to parallel previous experience. Samples were analyzed as shown in Fig. 1B .
Flow cytometry
After culture setup of the "baseline," "BC1," and "BC2" samples into duplicate T25 flasks, one set of flasks was harvested the following day (Day 1) and the second set was harvested 3 days after setup. On the respective day of harvest, the cells were removed from each flask and centrifuged for 5 minutes at 250 3 g. Each pellet was resuspended with 0.6 mL of prepared 13 annexin buffer (Cat # V13241, Vybrant apoptosis assay kit #2, Life Technologies) and placed on ice. Cells were then incubated in 5 mL polypropylene flow cytometry tubes with annexin V Alexa Fluor 488 and propidium iodide at room temperature, in the dark, for 15 minutes then acquired on a flow cytometer (FACSCalibur, Becton Dickinson). Intact cells were gated on a forward scatter versus side scatter plot then analyzed for staining with the two markers. Dual-negative cells were considered to be nonapoptotic, annexin V only cells were considered to be in early apoptosis, and dualpositive cells were considered to be in late apoptosis or necrosis.
Cell proliferation by bromodeoxyuridine incorporation
A viable cell count was performed by trypan blue exclusion and cells were seeded at 2 3 10 5 cells per well in 96-well tissue culture plates. Two plates were set up for each sample (cell proliferation enzyme-linked immunosorbent assay bromodeoxyuridine [BrdU; colorimetric], Cat # 11-647-229, Roche Diagnostics). One plate was used for cell counting and viability and the other plate was treated with 20 mg/mL phytohemagglutinin (PHA) or left untreated. All plates were incubated for approximately 2 days at 37 6 28C in a 5 6 2% CO 2 atmosphere. Cells in the plates (PHA treated and untreated) were then labeled by the addition of BrdU to each well. The plates were then incubated for 18 6 2 hours at 37 6 28C in a 5 6 2% CO 2 atmosphere. After the 18 6 2-hour incubation, plates were centrifuged and cells were treated with fixative for 30 6 5 minutes. After the 30 6 5 minutes, the fixed cells were treated with anti-BrdU-peroxidase for 90 6 10 minutes in the dark. After the incubation, wells were washed three times with wash buffer. Washed wells were then treated with substrate solution for 3 to 10 minutes on an orbital shaker. To stop development, 2.0 N sulfuric acid was added to each well and the plates were read on a plate reader at 450 nm with a reference of 690 nm.
Statistical analysis
The data were analyzed with computer software (SAS 9.2, SAS Institute). The p value of less than 0.05 was considered to be significant. Value and analysis of variance was done in computer software (SAS 9.2) using procedure generalized linear models. The pre-ECP BC sample serves as each subject's baseline reference.
RESULTS
Fourteen evaluable collections (XTS, n 5 8; CELLEX, n 5 6) were performed at the two study sites. There were no unexpected or serious events during the study. There were two different subjects who experienced an adverse event during the study. Both events were listed as mild, not serious, and no action was taken for either of the events. The first was an adverse device effect where the subject stated that they experienced an episode of fatigue after the procedure. The fatigue was completely resolved by the time of follow-up. No action was taken and the event was listed as mild. The second was classified as an adverse event where the subject developed a bruise at the site of infusion. The bruise was completely resolved by the time of the second follow-up. No action was taken and the event was listed as mild, completely related to ECP, and not related to ECP volume shift.
Apoptosis by annexin V binding and propidium iodide staining
Measurements of annexin and propidium iodide were taken at two different time points, Day 1 and Day 3, during the culture period to assess overall viability, relative levels of apoptosis of the cultured cells. The total number of samples analyzed were as follows: at baseline-14 total, eight XTS and six CELLEX; at BC1-13 total, seven XTS, six CELLEX; and at BC2-14 total, eight XTS, six CELLEX. One XTS BC1 sample is not part of the analysis due to lack of BC1 sample collection by the site. A typical phenotyping analysis with summary combined data is shown in Fig. 2 . There was no significant difference in the distributions of viable and apoptotic cells for the two instruments (Table 2) . Photoactivated BC2 cells had greater apoptosis and loss of cell viability compared to nontreated BC1.
Proliferative potential XTS 1 CELLEX
Mean percent relative inhibition was 97% with values ranging from 91% to 100% when BC2 was compared to BC1 and 98% with values ranging from 91% to 100% when BC2 was compared to baseline (Fig. 3) .
XTS
Mean percent relative inhibition was 97% with values ranging from 95% to 99% when BC2 was compared to BC1 and 98% with values ranging from 95% to 100% when BC2 was compared to baseline.
CELLEX
Mean percent relative inhibition was 97% with values ranging from 91% to 100% when BC2 was compared to BC1 and 98% with values ranging from 91% to 100% when BC2 was compared to baseline. When the relative percent inhibition results from the XTS samples were compared to the CELLEX samples, the systems were found to be equivalent for both sets of comparisons (BC2/BC1, p > 0.9 and BC2/baseline, p > 0.9) Inhibition of at least 90% is consistent with previous data (unpublished data on file) in which this degree of inhibition on Day 3 in culture in the presence of PHA was documented when methoxsalen/UVA-treated samples were compared to untreated control samples. The mean percent relative inhibition for BC2 was greater than 90% for all samples. Overall, the results were between 91 and 100%. Additionally, when the percent inhibition results of BC2/BC1 were compared to BC2/baseline, baseline and BC1 were found to be equivalent (p > 0.6). These results demonstrated that sufficient cell death was induced in the treated samples and more importantly, the mechanical processing alone did not induce significant cell death in the BC1 samples.
Cell viability using trypan blue
The mean proportion of viable cells for each instrument, as determined by trypan blue exclusion, is presented in Table 3 . Overall, the results indicate that there is a significant difference in cell viability after Day 0 between both baseline and BC1 samples when compared to BC2 samples (p < 0.0001 for all comparisons) when measured by trypan blue exclusion (Fig. 4) .
When BC1 samples were compared to the baseline samples, the trends were similar; however, there was a difference observed, especially at the Day 3 (p 5 0.001) and the Day 7 (p < 0.0001) time points. The difference (8) 67 (11) 64 (5) BC1 61 (11) 61 (4) 61 (6) BC2 3 (5) 6 (5) 2 (1) * Median (IQR) percentages are presented. between the baseline and BC1 results observed on Days 3 and 7 in the trypan blue exclusion assay may be attributed to: 1) differences in sample preparation and stability during shipping-the baseline was shipped as whole blood or 2) difference in level of necrosis-the trypan blue exclusion assay cannot distinguish between cell death by apoptosis or necrosis or a combination of both. With regard to the difference in sample preparation, the baseline samples required Ficoll preparation before placing the cells in culture. This process may have removed a subset of cells that were already dead or dying, potentially having an impact on the overall percent viability of the baseline samples. When percent viability results from XTS samples were compared to the percent viability results from CELLEX samples, the systems were found to be equivalent for all time points (p > 0. 
DISCUSSION
This study for the first time evaluates the effect of mechanical cell processing through the photopheresis instrument on induction of apoptosis, proliferation, and viability of MNCs. As indications for ECP increase, there is growing interest in the performance of sham ECP treatments; this is why the primary objective for this study was to assess the degree of apoptosis induced by the mechanical processes used for cell separation and processing of the BC.
The results of this study demonstrated a significant difference in apoptosis induction between the treated BC2 samples and the untreated BC1 samples as well as between the BC2 samples and the baseline samples with no significant difference in apoptosis induction between the baseline samples and the BC1. These results indicate that there is minimal impact on apoptosis induction by the mechanical processing of samples. Significant inhibition of cell proliferation was only observed when the BC was treated with psoralen and UVA. The mechanical processing did not affect the cell proliferation. The cell viability predictably was most significantly affected in the treated cell population, while the baseline and untreated cells behaved similarly on Day 0 and Day 1. The observed, unexpected, difference between the baseline and BC1 sample observed on Day 3 and Day 7 may have resulted from the technical issues related to cell processing before testing.
The secondary objective of this Phase I study was to compare the results observed from the XTS and CELLEX instruments to determine equivalence. The systems were shown to be equivalent in all three assays (p > 0.1 across all comparisons), which is important in the design of future clinical trials where both devices could be utilized.
One of the study limitations is inclusion of only male subjects. Although this was primarily driven by our risk assessment, we recognize that future studies should be designed to include both sexes. Interestingly, since this study has been completed a study pointing out differences in the rate of apoptosis generated by exposure to irradiation has been published. 25 In this study MNCs derived from females had a lower apoptosis rate (30.7%) than those derived from males (41%). It is unclear if the irradiation exposure has the same effect as photoactivation or mechanical injury, but it does raise the issue of sex-related resistance to apoptosis. However, the use of male subjects may have resulted in a more sensitive read-out in our study strengthening our conclusion. In summary, the results of this study indicate that there was a significantly lower, likely clinically irrelevant, level of apoptosis observed in the nonprocessed, untreated control samples (baseline) as well as the processed or untreated BC samples (BC1) compared to ECPtreated BC samples (BC2). Importantly, there was no difference between the two photopheresis systems, which could be of value in the design of future clinical trials.
